J&J Reaches $5.5B Talc Settlement to End Decade of Lawsuits

Johnson & Johnson announced Monday that it will pay an estimated $5.5 billion to resolve approximately 76,000 lawsuits alleging that its talc-based baby powder and other talc products caused ovarian cancer, in a landmark deal that could bring an end to more than a decade of litigation. According to NBC News, the settlement covers claims consolidated in federal court in New Jersey and related cases in state court, representing nearly all of the remaining talc claims against the company.

Context

The litigation began around 2011, when the first lawsuits alleged that J&J’s talcum powder products contained asbestos and caused ovarian cancer and mesothelioma. The company has consistently denied these claims, maintaining that its talc was safe and did not contain asbestos. J&J stopped selling talc-based baby powder in the U.S. and Canada in 2020, switching to a cornstarch-based product.

J&J previously pursued a controversial legal strategy known as the “Texas two-step,” creating a shell subsidiary called LTL Management that filed for bankruptcy in an attempt to cap payouts and force a global settlement. NBC News noted that three separate bankruptcy attempts all ended in dismissal by the courts, and the litigation resumed in March 2025 after being on hold for more than three years.

Key Developments

The settlement requires approval from at least 95% of ovarian cancer claimants in state or federal court before it becomes final. J&J expects to make an initial payment of no more than $3 billion in 2027, with further payments due in 2028. All claims are expected to be paid within 18 months, which is significantly faster than the timeline proposed under the bankruptcy plan.

The Associated Press reported that a U.S. bankruptcy court judge had previously denied a $9 billion settlement proposed by company subsidiary Red River Talc in 2025, and J&J decided not to appeal that ruling. The settlement announced Monday applies only to existing claims and does not address future lawsuits, a distinction that made more money available to current plaintiffs.

Chris Seeger, an attorney representing approximately 2,500 clients with talc claims who helped negotiate the agreement, told NBC News that J&J could ultimately pay $7 billion or more. “We got a fair settlement, and our clients are going to be happy with it,” Seeger said.

The Legal Path to Settlement

J&J reached the settlement after a series of courtroom victories. The company won individual trials, successfully disqualified plaintiffs’ lawyers from the litigation, and secured court rulings against expert witnesses that plaintiffs had used to prove their cases. NBC News reported that a federal judge cast doubt on individual plaintiffs’ ability to prove that talc specifically caused their ovarian cancer, placing claimants in a difficult position.

Erik Haas, J&J’s worldwide vice president of litigation, said in a prepared statement that the claims were “meritless” and that the company was willing to settle in order to obtain closure. “While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives,” Haas said, as reported by the Associated Press.

The company previously settled most mesothelioma-related claims, all state consumer protection claims, and all talc-supplier disputes. Before the bankruptcy strategy, J&J had a mixed record in talc trials, including a multibillion-dollar verdict in favor of 22 women who said baby powder caused their ovarian cancer, as The Guardian reported. The company won some trials outright and had other verdicts reduced on appeal.

Implications

This settlement represents one of the largest mass tort resolutions in U.S. history, resolving over 99% of pending talc claims. It marks a significant shift from J&J’s aggressive bankruptcy strategy to a traditional negotiated settlement. For J&J, a company with annual revenues exceeding $90 billion, the $5.5 billion payout is manageable and removes a major overhang that has weighed on its stock for years. The Associated Press noted that J&J shares rose more than 2% before the market open on the day of the announcement.

For plaintiffs, the settlement offers a faster resolution—within 18 months rather than the decade-plus timeline under the bankruptcy plan—and potentially higher individual payouts. However, claimants must weigh accepting the settlement against continuing to press their cases in court, particularly given recent adverse court rulings.

What’s Next

The critical question now is whether at least 95% of eligible claimants will accept the settlement. If the threshold is not met, the deal collapses and the litigation continues. Additionally, because the settlement only covers existing claims, future claimants who develop ovarian cancer will not be covered. The case highlights the ongoing tension between scientific uncertainty regarding the link between talc and ovarian cancer and the legal system’s approach to mass torts, and J&J’s failed “Texas two-step” strategy may discourage other companies from attempting similar bankruptcy maneuvers.